These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 16155010)

  • 21. Effect of age and previous autologous transplantation on nonrelapse mortality and survival in patients treated with reduced-intensity conditioning and allografting for advanced hematologic malignancies.
    Corradini P; Zallio F; Mariotti J; Farina L; Bregni M; Valagussa P; Ciceri F; Bacigalupo A; Dodero A; Lucesole M; Patriarca F; Rambaldi A; Scimè R; Locasciulli A; Bandini G; Gianni AM; Tarella C; Olivieri A
    J Clin Oncol; 2005 Sep; 23(27):6690-8. PubMed ID: 16170177
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Does younger donor age affect the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies beneficially?
    Mehta J; Gordon LI; Tallman MS; Winter JN; Evens AM; Frankfurt O; Williams SF; Grinblatt D; Kaminer L; Meagher R; Singhal S
    Bone Marrow Transplant; 2006 Jul; 38(2):95-100. PubMed ID: 16751789
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
    Michallet M; Le QH; Mohty M; Prébet T; Nicolini F; Boiron JM; Esperou H; Attal M; Milpied N; Lioure B; Bordigoni P; Yakoub-Agha I; Bourhis JH; Rio B; Deconinck E; Renaud M; Chir Z; Blaise D
    Exp Hematol; 2008 May; 36(5):535-44. PubMed ID: 18346838
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies.
    Huang XJ; Liu DH; Liu KY; Xu LP; Chen H; Han W; Chen YH; Wang JZ; Gao ZY; Zhang YC; Jiang Q; Shi HX; Lu DP
    Bone Marrow Transplant; 2006 Aug; 38(4):291-7. PubMed ID: 16883312
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Peripheral blood stem cell transplantation.
    Raina V
    Indian J Pediatr; 1996; 63(3):349-50. PubMed ID: 10830009
    [No Abstract]   [Full Text] [Related]  

  • 26. Advances and challenges in infectious diseases supportive care of patients with hematologic malignancies, hematopoietic stem cell transplantation, and severe aplastic anemia.
    Walsh TJ
    Semin Hematol; 2009 Jul; 46(3):191-7. PubMed ID: 19549573
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MHC class I, II, and III microsatellite marker matching and survival in unrelated donor hematopoietic cell transplantation.
    Malkki M; Gooley T; Horowitz M; Petersdorf EW;
    Tissue Antigens; 2007 Apr; 69 Suppl 1():46-9. PubMed ID: 17445162
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution.
    Rizzieri DA; Koh LP; Long GD; Gasparetto C; Sullivan KM; Horwitz M; Chute J; Smith C; Gong JZ; Lagoo A; Niedzwiecki D; Dowell JM; Waters-Pick B; Liu C; Marshall D; Vredenburgh JJ; Gockerman J; Decastro C; Moore J; Chao NJ
    J Clin Oncol; 2007 Feb; 25(6):690-7. PubMed ID: 17228020
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparable long-term survival after bone marrow versus peripheral blood progenitor cell transplantation from matched unrelated donors in children with hematologic malignancies.
    Meisel R; Laws HJ; Balzer S; Bernbeck B; Kramm C; Schönberger S; Sinha K; Tröger A; Schmitz M; Fischer J; Göbel U; Enczmann J; Dilloo D
    Biol Blood Marrow Transplant; 2007 Nov; 13(11):1338-45. PubMed ID: 17950920
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reduced-intensity conditioning regimen using low-dose total body irradiation before allogeneic transplant for hematologic malignancies: Experience from the European Group for Blood and Marrow Transplantation.
    Belkacémi Y; Labopin M; Hennequin C; Hoffstetter S; Mungai R; Wygoda M; Lundell M; Finke J; Aktinson C; Lorchel F; Durdux C; Basara N
    Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):544-51. PubMed ID: 17141976
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Unrelated umbilical cord blood transplantation using a TBI/FLAG conditioning regimen for adults with hematologic malignancies.
    Okada M; Fujimori Y; Misawa M; Kai S; Nakajima T; Okikawa Y; Satake A; Itoi H; Takatsuka H; Itsukuma T; Nishioka K; Tamaki H; Ikegame K; Hara H; Ogawa H
    Biol Blood Marrow Transplant; 2008 Aug; 14(8):896-903. PubMed ID: 18640573
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gene therapy for lympho-hematopoietic disorders.
    Thrasher AJ; Gaspar HB
    Curr Hematol Rep; 2005 Jul; 4(4):305-9. PubMed ID: 16009046
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Disparity in survival outcome after hematopoietic stem cell transplantation for hematologic malignancies according to area of primary residence.
    Rao K; Darrington DL; Schumacher JJ; Devetten M; Vose JM; Loberiza FR
    Biol Blood Marrow Transplant; 2007 Dec; 13(12):1508-14. PubMed ID: 18022581
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Haematopoietic stem cell transplantation for severe autoimmune diseases: new perspectives.
    Névessignsky MT; Ferster A
    Nephrol Dial Transplant; 2006 May; 21(5):1154-7. PubMed ID: 16431888
    [No Abstract]   [Full Text] [Related]  

  • 35. [Nonmyeloablative stem cell transplantation as cancer immunotherapy].
    Willems E; Baron F; Vanstraelen G; Frère P; Fillet G; Beguin Y
    Rev Med Suisse; 2005 Aug; 1(30):1973-7. PubMed ID: 16200942
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune reconstitution following myeloablative allogeneic hematopoietic stem cell transplantation: the impact of expanding CD28negative CD8+ T cells on relapse.
    Yakoub-Agha I; Saule P; Magro L; Cracco P; Duhamel A; Coiteux V; Bruno B; Dufossé F; Jouet JP; Dessaint JP; Labalette M
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):496-504. PubMed ID: 19285638
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interleukin-2 in the treatment of hematologic malignancies.
    Fefer A
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S31-2. PubMed ID: 10685655
    [No Abstract]   [Full Text] [Related]  

  • 38. Significance of eosinophilia after stem cell transplantation as a possible prognostic marker for favorable outcome.
    Sato T; Kobayashi R; Nakajima M; Iguchi A; Ariga T
    Bone Marrow Transplant; 2005 Dec; 36(11):985-91. PubMed ID: 16184178
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy.
    Trifilio SM; Bennett CL; Yarnold PR; McKoy JM; Parada J; Mehta J; Chamilos G; Palella F; Kennedy L; Mullane K; Tallman MS; Evens A; Scheetz MH; Blum W; Kontoyiannis DP
    Bone Marrow Transplant; 2007 Apr; 39(7):425-9. PubMed ID: 17310132
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
    Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH
    Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.